Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07135687 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 2027 to Oct 2028
    • Start date: Oct 2025 to Aug 2026
    • Study completion date: Dec 2027 to Dec 2028
    v3
  2. Phase: Not applicable to Phase 4
    • Study description revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair surgery of their knee.
Trial Details
NCT Number NCT07135687
Lead Sponsor Rush University Medical Center
Collaborators: Arthroscopy Association of North America
Conditions
(from sponsor)		 ACL Injury, ACL Reconstruction, Scar Formation
Related terms Anterior Cruciate Ligament Injuries
Enrollment 144 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov